Orally Disintegrating Tablet Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has conducted a thorough analysis of the Orally Disintegrating Tablet Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Orally Disintegrating Tablet Market spanning from 2024 to 2031.

The forecast suggests that the Global Orally Disintegrating Tablet Market will surpass US$ 40932.54 million by 2031, with a Compound Annual Growth Rate (CAGR) of 8.5%. In the pharmaceutical industry, oral drug administration remains the standard method due to its cost-effectiveness, simplicity, and safety.

Key Insights:

Orally Disintegrating Tablet Market Size (2024): US$ 23105.4 million
Projected Market Value (2031): US$ 40932.54 million
Global Market Growth Rate (CAGR 2024-2031): 8.5%

Orally Disintegrating Tablet Market - Report Scope:

Orally disintegrating tablets (ODTs) are pharmaceutical dosage forms that disintegrate or dissolve rapidly in the mouth without the need for water. These tablets are designed to enhance patient compliance, especially in populations such as pediatrics, geriatrics, and patients with swallowing difficulties. The orally disintegrating tablet market caters to pharmaceutical companies, healthcare providers, and consumers, offering a wide range of formulations and therapeutic categories.

Market Growth Drivers:

The global orally disintegrating tablet market is propelled by growing demand for pediatric and geriatric formulations, as well as the need for patient-friendly dosage forms for individuals with swallowing difficulties or aversion to conventional tablets. The rising incidence of chronic diseases, such as cardiovascular disorders, mental health conditions, and allergies, drives the development of orally disintegrating tablets across various therapeutic areas.

Technological advancements in formulation and manufacturing processes, such as taste-masking techniques, superdisintegrants, and freeze-drying technology, improve the palatability, stability, and disintegration properties of ODTs, enhancing patient acceptance and compliance. Additionally, strategic partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) facilitate the development and commercialization of innovative ODT formulations, further fueling market growth.

Market Restraints:

Despite promising growth prospects, the orally disintegrating tablet market faces challenges related to formulation complexity, regulatory compliance, and cost constraints. Developing ODT formulations with adequate mechanical strength, rapid disintegration, and acceptable taste profiles presents formulation challenges for pharmaceutical manufacturers, impacting product development timelines and costs.

Regulatory requirements for orally disintegrating tablets, including standards for dissolution testing, bioequivalence assessment, and stability studies, impose compliance burdens on manufacturers, affecting market entry barriers and time-to-market for new ODT products. Furthermore, reimbursement policies and pricing pressures in healthcare systems worldwide pose challenges for market penetration and profitability, particularly for generic ODT formulations in competitive markets.

Addressing these challenges requires collaboration between industry stakeholders, regulatory agencies, and healthcare providers to streamline regulatory pathways, harmonize quality standards, and ensure equitable access to affordable ODT formulations for patients worldwide.

Market Opportunities:

The orally disintegrating tablet market presents significant growth opportunities driven by demographic trends, consumer preferences, and technological innovations. The expansion of pediatric and geriatric populations, coupled with the increasing prevalence of chronic diseases and mental health disorders, creates a robust demand for patient-friendly dosage forms, such as orally disintegrating tablets.

Moreover, the emergence of personalized medicine and precision dosing approaches opens new avenues for ODT development, catering to individual patient needs and treatment preferences. Advanced formulation technologies, including 3D printing, nanotechnology, and co-crystallization techniques, enable the development of customized ODT formulations with enhanced bioavailability, controlled release, and targeted drug delivery profiles.

Strategic collaborations between pharmaceutical companies, academic institutions, and technology partners facilitate research and innovation in the orally disintegrating tablet space, driving product differentiation and market expansion. Furthermore, investments in digital health technologies, such as telemedicine platforms and mobile health apps, enhance patient engagement and medication adherence, creating synergies with ODT therapies and improving treatment outcomes.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the orally disintegrating tablet market globally?
Which therapeutic categories and formulations are driving ODT adoption across different patient populations?
How are technological advancements reshaping the competitive landscape of the orally disintegrating tablet market?
Who are the key players contributing to the orally disintegrating tablet market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global orally disintegrating tablet market?

Competitive Intelligence and Business Strategy:

Leading players in the global orally disintegrating tablet market, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., and AstraZeneca plc, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in research and development to develop novel ODT formulations, leveraging proprietary technologies and therapeutic expertise to address unmet medical needs and market opportunities.

Collaborations with contract research organizations (CROs), academic institutions, and regulatory agencies facilitate preclinical and clinical development of ODT products, expediting regulatory approval and market entry. Moreover, investments in manufacturing capabilities, quality assurance systems, and supply chain optimization enhance operational efficiency and ensure consistent product quality across global markets.

Key Companies Profiled

Teva Pharmaceutical Industries Ltd.
Novartis AG
AstraZeneca
Mylan N.V.
Pfizer Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bausch Health
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Bayer AG
Eli Lily and Company
Dr. Reddy's Laboratories Ltd.
Takeda Pharmaceutical Company Limited

Orally Disintegrating Tablet Market Categorization

Orally Disintegrating Tablet Market By Drug Class

Anti-Psychotics
Anti-Epileptics
CNS Stimulants
Anxiolytics
Anti-Parkinsonian Drugs
Anti-Hypertensives
NSAIDS
Anti-Allergy Drugs
Proton Pump Inhibitors
Others

Orally Disintegrating Tablet Market By Disease Indication

CNS Diseases
GI Diseases
CVS Disorders
Allergy
Others

Orally Disintegrating Tablet Market By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

Orally Disintegrating Tablet Market By Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

Product Code: PMRREP14572

1. Executive Summary

1.1. Global Market Outlook
1.2. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Dynamics

3.1. Macro-Economic Factors
3.2. Drivers
- 3.2.1. Supply Side Drivers
- 3.2.2. Demand Side Drivers
3.3. Restraints
3.4. Opportunities
3.5. Trends

4. Key Inclusion

4.1. Formulation processes for Orally Disintegrating Tablets
4.2. Value Chain Analysis

5. Global Orally Disintegrating Tablets Market Value Analysis 2019-2023 and Forecast, 2024-2031

5.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
5.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 5.2.1. Y-o-Y Growth Trend Analysis
- 5.2.2. Absolute $ Opportunity Analysis

6. Global Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031, by Drug Class

6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2019-2023
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2023 - 2025
- 6.3.1. Anti-Psychotics
- 6.3.2. Anti-Epileptic's
- 6.3.3. CNS Stimulants
- 6.3.4. Anxiolytics
- 6.3.5. Anti-Parkinson Ian Drugs
- 6.3.6. Anti-Hypertensives
- 6.3.7. NSAIDS
- 6.3.8. Anti-Allergy Drugs
- 6.3.9. Proton Pump Inhibitor
- 6.3.10. Others
6.4. Market Attractiveness Analysis By Drug Class

7. Global Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031, by Disease Indication

7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2023 - 2025
- 7.3.1. Central Nervous System Diseases (CNS)
- 7.3.2. Gastrointestinal (GI) Diseases
- 7.3.3. Cardiovascular(CVS) Diseases
- 7.3.4. Allergy
- 7.3.5. Others
7.4. Market Attractiveness Analysis By Disease Indication

8. Global Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 - 2025
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail Pharmacy
- 8.3.3. Drug Stores
- 8.3.4. Online Pharmacy
8.4. Market Attractiveness Analysis By Distribution Channel

9. Global Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031, by Region

9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023 - 2025
- 9.3.1. North America
- 9.3.2. Latin America
- 9.3.3. Europe
- 9.3.4. Asia-Pacific
- 9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis By Region

10. North America Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031

10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 10.3.1. By Country
  - 10.3.1.1. U.S.
  - 10.3.1.2. Canada
- 10.3.2. By Drug Class
- 10.3.3. By Disease Indication
- 10.3.4. By Distribution Channel
10.4. Market Attractiveness Analysis
10.5. Drivers & Restraints: Impact Analysis
10.6. Partial List of Players with Product Intensity Map By Country

11. Latin America Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031

11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 11.3.1. By Country
  - 11.3.1.1. Brazil
  - 11.3.1.2. Mexico
  - 11.3.1.3. Rest of Latin America
- 11.3.2. By Drug Class
- 11.3.3. By Disease Indication
- 11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.5. Drivers & Restraints: Impact Analysis
11.6. Partial List of Players with Product Intensity Map By Country

12. Europe Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 12.3.1. By Country
  - 12.3.1.1. Germany
  - 12.3.1.2. U.K.
  - 12.3.1.3. France
  - 12.3.1.4. Italy
  - 12.3.1.5. Spain
  - 12.3.1.6. Russia
  - 12.3.1.7. Rest of Europe
- 12.3.2. By Drug Class
- 12.3.3. By Disease Indication
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Drivers & Restraints: Impact Analysis
12.6. Partial List of Players with Product Intensity Map By Country

13. Asia-Pacific Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 13.3.1. By Country
  - 13.3.1.1. China
  - 13.3.1.2. India
  - 13.3.1.3. Japan
  - 13.3.1.4. Australia & New Zealand
  - 13.3.1.5. Rest of Asia-Pacific
- 13.3.2. By Drug Class
- 13.3.3. By Disease Indication
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Drivers & Restraints: Impact Analysis
13.6. Partial List of Players with Product Intensity Map By Country

14. Middle East and Africa Orally Disintegrating Tablets Market Analysis 2019-2023 and Forecast 2024-2031

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 14.3.1. By Country
  - 14.3.1.1. GCC Countries
  - 14.3.1.2. South Africa
  - 14.3.1.3. Rest of MEA
- 14.3.2. By Drug Class
- 14.3.3. By Disease Indication
- 14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Drivers & Restraints: Impact Analysis
14.6. Partial List of Players with Product Intensity Map By Country

15. Competition Analysis

15.1. Company Share Analysis
15.2. Market Structure by Tier of Companies
15.3. Competition Dashboard
15.4. Competition Deep Dive
- 15.4.1. Teva Pharmaceutical Industries Ltd.
  - 15.4.1.1. Company Overview
  - 15.4.1.2. Segment Overview
  - 15.4.1.3. Product Offerings
  - 15.4.1.4. Financial Analysis
  - 15.4.1.5. Key Developments
  - 15.4.1.6. Strategy Overview
- 15.4.2. Novartis AG
  - 15.4.2.1. Company Overview
  - 15.4.2.2. Segment Overview
  - 15.4.2.3. Product Offerings
  - 15.4.2.4. Financial Analysis
  - 15.4.2.5. Key Developments
  - 15.4.2.6. Strategy Overview
- 15.4.3. AstraZeneca
  - 15.4.3.1. Company Overview
  - 15.4.3.2. Segment Overview
  - 15.4.3.3. Product Offerings
  - 15.4.3.4. Financial Analysis
  - 15.4.3.5. Key Developments
  - 15.4.3.6. Strategy Overview
- 15.4.4. Mylan N.V.
  - 15.4.4.1. Company Overview
  - 15.4.4.2. Segment Overview
  - 15.4.4.3. Product Offerings
  - 15.4.4.4. Financial Analysis
  - 15.4.4.5. Key Developments
  - 15.4.4.6. Strategy Overview
- 15.4.5. Pfizer Inc.
  - 15.4.5.1. Company Overview
  - 15.4.5.2. Segment Overview
  - 15.4.5.3. Product Offerings
  - 15.4.5.4. Financial Analysis
  - 15.4.5.5. Key Developments
  - 15.4.5.6. Strategy Overview
- 15.4.6. Johnson & Johnson Services, Inc.
  - 15.4.6.1. Company Overview
  - 15.4.6.2. Segment Overview
  - 15.4.6.3. Product Offerings
  - 15.4.6.4. Financial Analysis
  - 15.4.6.5. Key Developments
  - 15.4.6.6. Strategy Overview
- 15.4.7. F. Hoffmann-La Roche Ltd.
  - 15.4.7.1. Company Overview
  - 15.4.7.2. Segment Overview
  - 15.4.7.3. Product Offerings
  - 15.4.7.4. Financial Analysis
  - 15.4.7.5. Key Developments
  - 15.4.7.6. Strategy Overview
- 15.4.8. Merck & Co., Inc.
  - 15.4.8.1. Company Overview
  - 15.4.8.2. Segment Overview
  - 15.4.8.3. Product Offerings
  - 15.4.8.4. Financial Analysis
  - 15.4.8.5. Key Developments
  - 15.4.8.6. Strategy Overview
- 15.4.9. Bausch Health
  - 15.4.9.1. Company Overview
  - 15.4.9.2. Segment Overview
  - 15.4.9.3. Product Offerings
  - 15.4.9.4. Financial Analysis
  - 15.4.9.5. Key Developments
  - 15.4.9.6. Strategy Overview
- 15.4.10. GlaxoSmithKline plc.
  - 15.4.10.1. Company Overview
  - 15.4.10.2. Segment Overview
  - 15.4.10.3. Product Offerings
  - 15.4.10.4. Financial Analysis
  - 15.4.10.5. Key Developments
  - 15.4.10.6. Strategy Overview
- 15.4.11. Sun Pharmaceutical Industries Ltd.
  - 15.4.11.1. Company Overview
  - 15.4.11.2. Segment Overview
  - 15.4.11.3. Product Offerings
  - 15.4.11.4. Financial Analysis
  - 15.4.11.5. Key Developments
  - 15.4.11.6. Strategy Overview
- 15.4.12. Bayer AG
  - 15.4.12.1. Company Overview
  - 15.4.12.2. Segment Overview
  - 15.4.12.3. Product Offerings
  - 15.4.12.4. Financial Analysis
  - 15.4.12.5. Key Developments
  - 15.4.12.6. Strategy Overview
- 15.4.13. Eli Lily and Company
  - 15.4.13.1. Company Overview
  - 15.4.13.2. Segment Overview
  - 15.4.13.3. Product Offerings
  - 15.4.13.4. Financial Analysis
  - 15.4.13.5. Key Developments
  - 15.4.13.6. Strategy Overview
- 15.4.14. Dr. Reddy's Laboratories Ltd.
  - 15.4.14.1. Company Overview
  - 15.4.14.2. Segment Overview
  - 15.4.14.3. Product Offerings
  - 15.4.14.4. Financial Analysis
  - 15.4.14.5. Key Developments
  - 15.4.14.6. Strategy Overview
- 15.4.15. Takeda Pharmaceutical Company Limited
  - 15.4.15.1. Company Overview
  - 15.4.15.2. Segment Overview
  - 15.4.15.3. Product Offerings
  - 15.4.15.4. Financial Analysis
  - 15.4.15.5. Key Developments
  - 15.4.15.6. Strategy Overview